{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:24:08Z","timestamp":1790209448842,"version":"4.1.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T00:00:00Z","timestamp":1712534400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Sonderegger Research Center for Improved Medication Outcomes"},{"name":"Joseph B. Wiederholt Fellowship"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Addict Sci Clin Pract"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Pharmacy-based screening and brief interventions (SBI) offer opportunities to identify opioid misuse and opioid safety risks and provide brief interventions that do not overly burden pharmacists. Currently, such interventions are being developed without patient input and in-depth contextual data and insufficient translation into practice. The purpose of this study is to qualitatively explore and compare patient and pharmacist perceptions and needs regarding a pharmacy-based opioid misuse SBI and to identify relevant SBI features and future implementation strategies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Using the Consolidated Framework for Implementation Research, we conducted semi-structured interviews with 8 patients and 11 pharmacists, to explore needs and barriers to participating in a pharmacy-based SBI. We recruited a purposive sample of English-speaking patients prescribed opioids for chronic or acute pain and pharmacists practicing in varied pharmacies (small independent, large-chain, specialty retail) settings. We used an inductive content analysis approach to analyze patient interview data. Then through a template analysis approach involving comparison of pharmacist and patient themes, we developed strategies for SBI implementation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Most patient participants were white, older, described living in suburban areas, and were long-term opioid users. We identified template themes related to individual, interpersonal, intervention, and implementation factors and inferred\u00a0applications for SBI design or potential SBI implementation strategies. We found that patients needed education on opioid safety and general opioid use, regardless of opioid use behaviors. Pharmacists described needing patient-centered training, protocols, and scripts to provide SBI. A short-self-reported screening and brief interventions including counseling, naloxone, and involving prescribers were discussed by both groups.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Through this implementation-focused qualitative study, we identified patient needs such as opioid safety education delivered in a private and convenient format and pharmacist needs including training, workflow integration, protocols, and a time-efficient intervention for effective pharmacy-based SBI. Alternate formats of SBI using digital health technologies may be needed for effective implementation. Our findings can be used to develop patient-centered pharmacy-based SBI that can be implemented within actual pharmacy practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13722-024-00460-y","type":"journal-article","created":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T20:25:06Z","timestamp":1712607906000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Patient and pharmacist perspectives on opioid misuse screening and brief interventions in community pharmacies"],"prefix":"10.1186","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2927-7639","authenticated-orcid":false,"given":"Deepika","family":"Rao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James H.","family":"Ford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayinka O.","family":"Shiyanbola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,4,8]]},"reference":[{"key":"460_CR1","unstructured":"NIDA. Drug Overdose Death Rates: National Institute of Health; 2023. https:\/\/nida.nih.gov\/research-topics\/trends-statistics\/overdose-death-rates. Accessed 2 Feb 2023."},{"issue":"7","key":"460_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1007\/s11606-005-0105-5","volume":"20","author":"I Chen","year":"2005","unstructured":"Chen I, Kurz J, Pasanen M, Faselis C, Panda M, Staton LJ, et al. Racial differences in opioid use for chronic nonmalignant pain. J Gen Intern Med. 2005;20(7):593\u20138.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"460_CR3","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1111\/jphs.12013","volume":"4","author":"G Cochran","year":"2013","unstructured":"Cochran G, Field C, Lawson K, Erickson C. Pharmacists\u2019 knowledge, attitudes and beliefs regarding screening and brief intervention for prescription opioid abuse: a survey of U tah and T exas pharmacists. J Pharm Health Serv Res. 2013;4(2):71\u20139.","journal-title":"J Pharm Health Serv Res"},{"key":"460_CR4","first-page":"1","volume":"42","author":"D Rao","year":"2020","unstructured":"Rao D, Giannetti V, Kamal KM, Covvey JR, Tomko JR. The relationship between knowledge, attitudes, and practices of community pharmacists regarding persons with substance use disorders. Subst Abuse. 2021;42(4):630\u20137.","journal-title":"Subst Abuse"},{"key":"460_CR5","doi-asserted-by":"publisher","first-page":"108729","DOI":"10.1016\/j.drugalcdep.2021.108729","volume":"224","author":"NJ Kazerouni","year":"2021","unstructured":"Kazerouni NJ, Irwin AN, Levander XA, Geddes J, Johnston K, Gostanian CJ, et al. Pharmacy-related buprenorphine access barriers: an audit of pharmacies in counties with a high opioid overdose burden. Drug Alcohol Depend. 2021;224:108729.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"460_CR6","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s13722-019-0158-0","volume":"14","author":"P Bach","year":"2019","unstructured":"Bach P, Hartung D. Leveraging the role of community pharmacists in the prevention, surveillance, and treatment of opioid use disorders. Addict Sci Clin Pract. 2019;14(1):30.","journal-title":"Addict Sci Clin Pract"},{"issue":"2","key":"460_CR7","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.sapharm.2015.05.008","volume":"12","author":"CW Norwood","year":"2016","unstructured":"Norwood CW, Wright ER. Integration of prescription drug monitoring programs (PDMP) in pharmacy practice: improving clinical decision-making and supporting a pharmacist\u2019s professional judgment. Res Social Adm Pharm. 2016;12(2):257\u201366.","journal-title":"Res Social Adm Pharm"},{"issue":"5","key":"460_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1016\/j.japh.2018.06.003","volume":"58","author":"K Johnston","year":"2018","unstructured":"Johnston K, Alley L, Novak K, Haverly S, Irwin A, Hartung D. Pharmacists\u2019 attitudes, knowledge, utilization, and outcomes involving prescription drug monitoring programs: a brief scoping review. J Am Pharm Assoc. 2018;58(5):568\u201376.","journal-title":"J Am Pharm Assoc"},{"key":"460_CR9","doi-asserted-by":"publisher","first-page":"103146","DOI":"10.1016\/j.drugpo.2021.103146","volume":"92","author":"T Antoniou","year":"2021","unstructured":"Antoniou T, Pritlove C, Shearer D, Martins D, Tadrous M, Munro C, et al. A qualitative study of a publicly funded pharmacy-dispensed naloxone program. Int J Drug Polic. 2021;92:103146.","journal-title":"Int J Drug Polic"},{"issue":"31","key":"460_CR10","doi-asserted-by":"publisher","first-page":"679","DOI":"10.15585\/mmwr.mm6831e1","volume":"68","author":"GP Guy Jr","year":"2019","unstructured":"Guy GP Jr, Haegerich TM, Evans ME, Losby JL, Young R, Jones CM. Vital signs: pharmacy-based naloxone dispensing\u2014United States, 2012\u20132018. Morb Mortal Wkly Rep. 2019;68(31):679.","journal-title":"Morb Mortal Wkly Rep"},{"issue":"1","key":"460_CR11","first-page":"1682","volume":"18","author":"JD Thornton","year":"2020","unstructured":"Thornton JD, Anyanwu P, Tata V, Al Rawwad T, Fleming ML. Differences between pharmacists\u2019 perception of counseling and practice in the era of prescription drug misuse. Pharm Pract. 2020;18(1):1682.","journal-title":"Pharm Pract"},{"issue":"4","key":"460_CR12","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1080\/08897077.2019.1694618","volume":"40","author":"J Bratberg","year":"2019","unstructured":"Bratberg J. Pharmacy: addressing substance use in the 21st century. Subst Abuse. 2019;40(4):421\u201334.","journal-title":"Subst Abuse"},{"issue":"9","key":"460_CR13","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1093\/pm\/pnx139","volume":"19","author":"DM Hartung","year":"2017","unstructured":"Hartung DM, Hall J, Haverly SN, Cameron D, Alley L, Hildebran C, et al. Pharmacists\u2019 role in opioid safety: a focus group investigation. Pain Med. 2017;19(9):1799\u2013806.","journal-title":"Pain Med"},{"key":"460_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.sapharm.2023.05.003","author":"D Rao","year":"2023","unstructured":"Rao D, Mercy M, McAtee C, Ford JH, Shiyanbola OO. A scoping literature review of pharmacy-based opioid misuse screening and brief interventions. Res Soc Adm Pharm. 2023. https:\/\/doi.org\/10.1016\/j.sapharm.2023.05.003.","journal-title":"Res Soc Adm Pharm"},{"issue":"1","key":"460_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0898010111412189","volume":"30","author":"S Morgan","year":"2012","unstructured":"Morgan S, Yoder LH. A concept analysis of person-centered care. J Holist Nurs. 2012;30(1):6\u201315.","journal-title":"J Holist Nurs"},{"issue":"9","key":"460_CR16","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.2105\/AJPH.2012.301165","volume":"103","author":"RC Brownson","year":"2013","unstructured":"Brownson RC, Jacobs JA, Tabak RG, Hoehner CM, Stamatakis KA. Designing for dissemination among public health researchers: findings from a national survey in the United States. Am J Public Health. 2013;103(9):1693\u20139.","journal-title":"Am J Public Health"},{"key":"460_CR17","unstructured":"CFIR. Consolidated framework for implementation research interview guide Ann Arbor, MI: CFIR Research Team-Center for Clinical Management Research. https:\/\/cfirguide.org\/guide\/app\/#\/. Accessed December 2020."},{"issue":"10","key":"460_CR18","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1080\/08870440903194015","volume":"25","author":"JJ Francis","year":"2010","unstructured":"Francis JJ, Johnston M, Robertson C, Glidewell L, Entwistle V, Eccles MP, et al. What is an adequate sample size? Operationalising data saturation for theory-based interview studies. Psychol Health. 2010;25(10):1229\u201345.","journal-title":"Psychol Health"},{"issue":"13","key":"460_CR19","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1177\/1049732315617444","volume":"26","author":"K Malterud","year":"2016","unstructured":"Malterud K, Siersma VD, Guassora AD. Sample size in qualitative interview studies: guided by information power. Qual Health Res. 2016;26(13):1753\u201360.","journal-title":"Qual Health Res"},{"key":"460_CR20","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s10488-013-0528-y","volume":"42","author":"LA Palinkas","year":"2015","unstructured":"Palinkas LA, Horwitz SM, Green CA, Wisdom JP, Duan N, Hoagwood K. Purposeful sampling for qualitative data collection and analysis in mixed method implementation research. Adm Polic Mental Health Mental Health Serv Res. 2015;42:533\u201344.","journal-title":"Adm Polic Mental Health Mental Health Serv Res"},{"issue":"9","key":"460_CR21","first-page":"1408","volume":"20","author":"PI Fusch","year":"2015","unstructured":"Fusch PI, Ness LR. Are we there yet? Data saturation in qualitative research. Qual Rep. 2015;20(9):1408\u201316.","journal-title":"Qual Rep"},{"issue":"1","key":"460_CR22","first-page":"24","volume":"45","author":"D Rao","year":"2024","unstructured":"Rao D, McAtee C, Mercy M, Shiyanbola OO, Ford JH. An implementation-focused qualitative exploration of pharmacist needs regarding an opioid use disorder screening and brief intervention. Subst Use Addctn J. 2024;45(1):24\u201332.","journal-title":"Subst Use Addctn J"},{"key":"460_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/0147-1767(85)90062-8","volume-title":"Naturalistic inquiry","author":"YS Lincoln","year":"1985","unstructured":"Lincoln YS, Guba EG. Naturalistic inquiry. Newbury Park, CA: Sage Publications; 1985."},{"issue":"6","key":"460_CR24","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","volume":"19","author":"A Tong","year":"2007","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","journal-title":"Int J Qual Health Care"},{"issue":"15","key":"460_CR25","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1001\/jama.2016.1464","volume":"315","author":"D Dowell","year":"2016","unstructured":"Dowell D, Haegerich TM, Chou R. CDC guideline for prescribing opioids for chronic pain\u2014United States, 2016. JAMA. 2016;315(15):1624\u201345.","journal-title":"JAMA"},{"issue":"8","key":"460_CR26","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1093\/pm\/pnv083","volume":"17","author":"DZ Buchman","year":"2016","unstructured":"Buchman DZ, Ho A, Illes J. You present like a drug addict: patient and clinician perspectives on trust and trustworthiness in chronic pain management. Pain Med. 2016;17(8):1394\u2013406.","journal-title":"Pain Med"},{"issue":"4","key":"460_CR27","doi-asserted-by":"publisher","first-page":"578","DOI":"10.3122\/jabfm.2018.04.180021","volume":"31","author":"KJ Sherman","year":"2018","unstructured":"Sherman KJ, Walker RL, Saunders K, Shortreed SM, Parchman M, Hansen RN, et al. Doctor-patient trust among chronic pain patients on chronic opioid therapy after opioid risk reduction initiatives: a survey. J Am Board Family Med. 2018;31(4):578\u201387.","journal-title":"J Am Board Family Med"},{"issue":"8","key":"460_CR28","first-page":"1505","volume":"18","author":"KE Dunn","year":"2017","unstructured":"Dunn KE, Barrett FS, Fingerhood M, Bigelow GE. Opioid overdose history, risk behaviors, and knowledge in patients taking prescribed opioids for chronic pain. Pain Med. 2017;18(8):1505\u201315.","journal-title":"Pain Med"},{"issue":"3","key":"460_CR29","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/pm\/pnx021","volume":"19","author":"S Nielsen","year":"2018","unstructured":"Nielsen S, Peacock A, Lintzeris N, Bruno R, Larance B, Degenhardt L. Knowledge of opioid overdose and attitudes to supply of take-home naloxone among people with chronic noncancer pain prescribed opioids. Pain Med. 2018;19(3):533\u201340.","journal-title":"Pain Med"},{"issue":"5","key":"460_CR30","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/ADM.0000000000000235","volume":"10","author":"KE Dunn","year":"2016","unstructured":"Dunn KE, Barrett FS, Yepez-Laubach C, Meyer AC, Hruska BJ, Sigmon SC, et al. Brief Opioid Overdose Knowledge (BOOK): a questionnaire to assess overdose knowledge in individuals who use illicit or prescribed opioids. J Addict Med. 2016;10(5):314.","journal-title":"J Addict Med"},{"issue":"9","key":"460_CR31","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.jpain.2005.04.004","volume":"6","author":"BM Schieffer","year":"2005","unstructured":"Schieffer BM, Pham Q, Labus J, Baria A, Van Vort W, Davis P, et al. Pain medication beliefs and medication misuse in chronic pain. J Pain. 2005;6(9):620\u20139.","journal-title":"J Pain"},{"key":"460_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2018.00034","author":"AS Huhn","year":"2018","unstructured":"Huhn AS, Garcia-Romeu AP, Dunn KE. Opioid overdose education for individuals prescribed opioids for pain management: randomized comparison of two computer-based interventions. Front Psychiatr. 2018. https:\/\/doi.org\/10.3389\/fpsyt.2018.00034.","journal-title":"Front Psychiatr"},{"key":"460_CR33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/08897077.2020.1866144","volume":"42","author":"A Werremeyer","year":"2021","unstructured":"Werremeyer A, Mosher S, Eukel H, Skoy E, Steig J, Frenzel O, et al. Pharmacists\u2019 stigma toward patients engaged in opioid misuse: When \u201csocial distance\u201d does not mean disease prevention. Subst Abuse. 2021;42(4):919\u201326.","journal-title":"Subst Abuse"},{"issue":"8","key":"460_CR34","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.sapharm.2019.11.012","volume":"16","author":"T Thakur","year":"2020","unstructured":"Thakur T, Chewning B. Using role theory to explore pharmacist role conflict in opioid risks communication. Res Social Adm Pharm. 2020;16(8):1121\u20136.","journal-title":"Res Social Adm Pharm"},{"issue":"1","key":"460_CR35","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1097\/CEH.0000000000000233","volume":"39","author":"HN Eukel","year":"2019","unstructured":"Eukel HN, Skoy E, Werremeyer A, Burck S, Strand M. Changes in pharmacists\u2019 perceptions after a training in opioid misuse and accidental overdose prevention. J Contin Educ Health Prof. 2019;39(1):7\u201312.","journal-title":"J Contin Educ Health Prof"},{"key":"460_CR36","doi-asserted-by":"publisher","first-page":"107570","DOI":"10.1016\/j.drugalcdep.2019.107570","volume":"205","author":"G Cochran","year":"2019","unstructured":"Cochran G, Chen Q, Field C, Seybert AL, Hruschak V, Jaber A, et al. A community pharmacy-led intervention for opioid medication misuse: a small-scale randomized clinical trial. Drug Alcohol Depend. 2019;205:107570.","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"460_CR37","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.japh.2018.03.005","volume":"58","author":"G Cochran","year":"2018","unstructured":"Cochran G, Field C, Karp J, Seybert AL, Chen Q, Ringwald W, et al. A community pharmacy intervention for opioid medication misuse: a pilot randomized clinical trial. J Am Pharm Assoc. 2018;58(4):395\u2013403.","journal-title":"J Am Pharm Assoc"},{"key":"460_CR38","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.09.003","author":"E Skoy","year":"2019","unstructured":"Skoy E, Eukel H, Werremeyer A, Strand M, Frenzel O, Steig J. Implementation of a statewide program within community pharmacies to prevent opioid misuse and accidental overdose. J Am Pharm Assoc. 2019. https:\/\/doi.org\/10.1016\/j.japh.2019.09.003.","journal-title":"J Am Pharm Assoc"},{"key":"460_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2019.09.003","author":"E Skoy","year":"2020","unstructured":"Skoy E, Werremeyer A, Steig J, Eukel H, Frenzel O, Strand M. Patient acceptance of naloxone resulting from targeted intervention from community pharmacists to prevent opioid misuse and accidental overdose. Subst Abus. 2021;42(4):672\u20137. https:\/\/doi.org\/10.1080\/08897077.2020.1827126.","journal-title":"Subst Abus"},{"issue":"6","key":"460_CR40","doi-asserted-by":"publisher","first-page":"861","DOI":"10.2105\/AJPH.2019.305060","volume":"109","author":"MA Strand","year":"2019","unstructured":"Strand MA, Eukel H. A primary prevention approach to the opioid epidemic. Am J Public Health. 2019;109(6):861\u20133.","journal-title":"Am J Public Health"},{"issue":"8","key":"460_CR41","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.sapharm.2018.07.011","volume":"15","author":"MA Strand","year":"2019","unstructured":"Strand MA, Eukel H, Burck S. Moving opioid misuse prevention upstream: a pilot study of community pharmacists screening for opioid misuse risk. Res Soc Adm Pharm. 2019;15(8):1032\u20136.","journal-title":"Res Soc Adm Pharm"},{"issue":"8","key":"460_CR42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.sapharm.2018.10.024","volume":"15","author":"S Nielsen","year":"2019","unstructured":"Nielsen S, Kowalski M, Wood P, Larney S, Bruno R, Shanahan M, et al. Routine opioid outcome monitoring in community pharmacy: pilot implementation study protocol. Res Soc Adm Pharm. 2019;15(8):1047\u201355.","journal-title":"Res Soc Adm Pharm"},{"key":"460_CR43","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11096-020-01074-5","volume":"43","author":"S Nielsen","year":"2020","unstructured":"Nielsen S, Sanfilippo P, Picco L, Bruno R, Kowalski M, Wood P, et al. What predicts pharmacists\u2019 engagement with opioid-outcome screening? Secondary analysis from an implementation study in community pharmacy. Int J Clin Pharm. 2021;43:420\u20139.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"460_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.24926\/iip.v10i1.1645","volume":"10","author":"WK Cornell","year":"2019","unstructured":"Cornell WK, Clauson KA, Cain J. Updating the model: the case for independent pharmacy to embrace digital health. Innov Pharm. 2019;10(1):15.","journal-title":"Innov Pharm"},{"issue":"1","key":"460_CR45","doi-asserted-by":"publisher","first-page":"32","DOI":"10.37901\/jcphp16-00012","volume":"64","author":"M Clark","year":"2017","unstructured":"Clark M, Clark T, Bhatti A, Aungst T. The rise of digital health and potential implications for pharmacy practice. J Contemp Pharm Pract. 2017;64(1):32\u201340.","journal-title":"J Contemp Pharm Pract"},{"key":"460_CR46","unstructured":"Naloxone: Understanding Its Role and Use in the Community. 2020. https:\/\/elearning.pharmacist.com\/products\/6000\/apha-pain-management-forum-2020-subscription. Accessed 21 Dec 2021."},{"issue":"14","key":"460_CR47","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1080\/10826084.2021.1968434","volume":"56","author":"D Rao","year":"2021","unstructured":"Rao D, Giannetti V, Kamal KM, Covvey JR, Tomko JR. Pharmacist views regarding the prescription opioid epidemic. Subst Use Misuse. 2021;56(14):2096\u2013105.","journal-title":"Subst Use Misuse"},{"issue":"1","key":"460_CR48","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1080\/08897077.2017.1365803","volume":"39","author":"NE Hagemeier","year":"2018","unstructured":"Hagemeier NE, Tudiver F, Brewster S, Hagy EJ, Ratliff B, Hagaman A, et al. Interprofessional prescription opioid abuse communication among prescribers and pharmacists: a qualitative analysis. Subst Abus. 2018;39(1):89\u201394.","journal-title":"Subst Abus"}],"container-title":["Addiction Science &amp; Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00460-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13722-024-00460-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13722-024-00460-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,8]],"date-time":"2024-04-08T21:02:18Z","timestamp":1712610138000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpjournal.biomedcentral.com\/articles\/10.1186\/s13722-024-00460-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["460"],"URL":"https:\/\/doi.org\/10.1186\/s13722-024-00460-y","relation":{},"ISSN":["1940-0640"],"issn-type":[{"value":"1940-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,8]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Institutional Review Board at University of Wisconsin-Madison approved the study procedures (Study ID: 2021-0091). Verbal informed consent was obtained prior to data collection.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27"}}